CHMP5 and COVID-19: Regarding the association between higher antibody titers and long-term COVID-19 symptoms, there are conflicting results in this area: data from studies by Horton et al., Peghin et al., and van Elslande et al. report elevated SARS-CoV-2-specific anti-spike and anti-nucleocapsid antibody levels in patients with post-COVID syndrome assessed up to 6 months after infection, while other studies, such as those by García-Abellán et al., show controversial findings with a weak anti-SARS-CoV-2 antibody response associated with long-COVID-19 [17,25,27,28,29,30].